CA-LIQUID-INSTRUMENTS
23.3.2021 14:02:04 CET | Business Wire | Press release
Today, Liquid Instruments , an innovator in precision software-defined instrumentation, launched Moku:Go , a complete, portable platform designed to bring the engineering lab anywhere and usher in a new era of scientific and engineering education at universities around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005031/en/
Within higher education, current in-person lab instrumentation is stationary, expensive, hardware-limited and fixed at the time of purchase. Existing portable solutions lack the intuitive software interfaces that current and future generations of students have come to expect. They also do not offer all of the necessary instruments and features to enable students to learn effectively outside of the lab. The increasing demand for remote learning solutions and a more hands-on experience both in and out of the classroom has fueled the market need for student-owned, flexible platforms that can support the next generation of engineers and scientists.
The new software-enabled hardware platform, Moku:Go, is an engineering lab that can fit in a backpack. It was designed for maximum portability, flexibility and durability, to take not just electrical engineering students, but physics, bioengineering, chemical engineering and other majors through all four years of their education and even beyond. It starts with 8 proven, powerful instruments including an oscilloscope, PID controller, logic analyzer, arbitrary waveform generator, data logger, spectrum analyzer, and more. It also features full connectivity with a Wi-Fi hotspot and USB-C, robust hardware features and electrical protection to ensure that students can explore new projects without putting themselves or their equipment at risk. The unique integrated power supplies are user programmable with high voltage and high current options for any project.
“Our students were thrilled when we first added Moku:Lab to our classroom two years ago, and after seeing the new capabilities of Moku:Go, I’m even more excited. It is clear that it will help take students’ educational experience into the modern era,” said Colonel Brian J. Neff, Electrical & Computer Engineering Department Head at the United States Air Force Academy. “I look forward to seeing this become a standard part of our curriculum.”
Moku:Go’s software was designed to appeal to a generation that is accustomed to intuitive user interfaces and broad compatibility. Liquid Instruments is bringing the user experience out of the flip-phone era and has designed intuitive Windows and Mac interfaces that are inviting and powerful for students. It offers remote access capabilities and clearly diagrammed views of the signal processing chain, which makes it easy for students to learn difficult concepts whether they are in person or remote. The student-centric design ensures they are learning the core concepts, rather than just learning the equipment itself.
Not only does Moku:Go help increase student engagement, but incorporation into curriculum also reduces faculty and teaching assistant workloads. The platform supports Python, LabVIEW and MATLAB APIs and has published examples of MATLAB live scripts for remote instruction, live student assistance and plagiarism control.
Its robust feature set and sophisticated software can also unlock advanced capabilities for makers and even high school students looking to explore engineering. Whether they are learning the basics of resistors and op-amps or designing an advanced quadcopter with sensors and autonomous navigation, Moku:Go enables easier access to otherwise complex concepts and hands-on engineering projects anytime, anywhere at an affordable price.
Liquid Instruments is introducing Moku:Go for science and engineering students as part of its growing product portfolio of high-precision instrumentation solutions developed by its team of experimental physicists and engineers that know firsthand what is necessary to transform the way learning and research is performed at all levels. The existing product, Moku:Lab, has been utilized for years by top institutions worldwide, enabling breakthrough research in the areas of photonics, electronics, and materials science.
“Our first product, Moku:Lab, gave R&D scientists the power and flexibility they needed to do their job, all in a streamlined and cost-effective platform. Now with Moku:Go we will bring those same advantages to improve the overall quality of education and motivate students to study science and engineering,” said Professor Daniel Shaddock, CEO and co-founder of Liquid Instruments. “Students deserve lab equipment that is powerful and flexible, but also simple and fun to use. Improving access to critical educational tools will empower students from all walks of life to pursue a career in STEM.”
Moku:Go starts at $499 and can be customized to match school colors, with volume purchasing for educational institutions. For information on education discounts, accessories and full specifications, please visit the product page here .
For more information about Liquid Instruments and its full suite of products, please visit https://liquidinstruments.com .
About Liquid Instruments
Liquid Instruments is a leader in precision software-defined instrumentation and is revolutionizing the way that scientists, engineers, and students expand their knowledge and conduct research & development. Their product line of hardware and software solutions leverages the computational power of modern FPGAs to create highly customizable instrumentation for controlling experiments and acquiring and analyzing data. The team’s IP in software-defined hardware enables Moku products to be dynamically reconfigurable in the field, serving a wide range of ever-changing experimental and process control situations. Moku:Lab is used by hundreds of top R&D institutions worldwide, and brings 12+ high-value instruments together into a compact, intuitive device that has greatly streamlined experimental workflows. For more information, please visit https://liquidinstruments.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
